Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TME Pharma NVXPAR:ALTME +2.96%24 EV-to-EBITDA is -6.46 as of Aug. 30, 2026. GuruFocus rates XPAR:ALTME with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 401 Biotechnology companies, TME Pharma NV ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TME Pharma NV's enterprise value is €14.12 Mil.
TME Pharma NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.19 Mil. Therefore, TME Pharma NV's EV-to-EBITDA for today is -6.46.
The historical rank and industry rank for TME Pharma NV's EV-to-EBITDA or its related term are showing as below:
XPAR:ALTME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.46 Med: 0.23 Max: 0.29
Current: -6.46
During the past 12 years, the highest EV-to-EBITDA of TME Pharma NV was 0.29. The lowest was -6.46. And the median was 0.23.
XPAR:ALTME's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 14.49
vs XPAR:ALTME: -6.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TME Pharma NV's PE Ratio (TTM) for today is calculated as:
TME Pharma NV's share price for today is €0.146.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for TME Pharma NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALTME vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, TME Pharma NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's EV-to-EBITDA falls into.
TME Pharma NV's current Enterprise Value is €14.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TME Pharma NV (XPAR:ALTME) has a EV-to-EBITDA of -6.46 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TME Pharma NV. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 401 companies in the Biotechnology industry.
Is TME Pharma NV's EV-to-EBITDA too high?
TME Pharma NV's current EV-to-EBITDA is -6.46. Based on the distribution chart, TME Pharma NV ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TME Pharma NV has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does TME Pharma NV's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 401 companies for EV-to-EBITDA. This places TME Pharma NV in the lower half of its industry. The industry median EV-to-EBITDA is 14.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.49, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TME Pharma NV. For the Biotechnology industry, the median EV-to-EBITDA is 14.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current EV-to-EBITDA is -6.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current EV-to-EBITDA of -6.46. The current EV-to-EBITDA is -6.46. TME Pharma NV's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current EV-to-EBITDA is -6.46 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
24GF Score
Get the complete analysis for XPAR:ALTME
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 
